These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31347936)

  • 21. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
    BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients.
    Chan DLH; Toh GLX; Goh LL
    Exp Mol Pathol; 2020 Oct; 116():104515. PubMed ID: 32738312
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Funazo T; Yasuda Y; Hirai T
    Anticancer Res; 2017 May; 37(5):2721-2725. PubMed ID: 28476851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
    Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
    Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.
    Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY
    Cancer Med; 2024 Jan; 13(1):e6870. PubMed ID: 38140788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
    Oxnard GR; Thress KS; Alden RS; Lawrance R; Paweletz CP; Cantarini M; Yang JC; Barrett JC; Jänne PA
    J Clin Oncol; 2016 Oct; 34(28):3375-82. PubMed ID: 27354477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
    Bordi P; Del Re M; Minari R; Rofi E; Buti S; Restante G; Squadrilli A; Crucitta S; Casartelli C; Gnetti L; Azzoni C; Bottarelli L; Petrini I; Cosenza A; Ferri L; Rapacchi E; Danesi R; Tiseo M
    Lung Cancer; 2019 May; 131():78-85. PubMed ID: 31027702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
    Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
    Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Analysis of the Efficacy of Rebiopsy and
    Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC
    Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
    Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
    Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
    Komiya K; Nakashima C; Nakamura T; Hirakawa H; Abe T; Ogusu S; Takahashi K; Takeda Y; Egashira Y; Kimura S; Sueoka-Aragane N
    Anticancer Res; 2018 Jun; 38(6):3559-3566. PubMed ID: 29848710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
    Su KY; Tseng JS; Liao KM; Yang TY; Chen KC; Hsu KH; Yang PC; Yu SL; Chang GC
    PLoS One; 2018; 13(11):e0207001. PubMed ID: 30444875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
    Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.